phosphodiesterase 3AGenealiases: CGI-PDE · CGI-PDE A · CGI-PDE-A · HTNB
Q-omics provides the consensus-scored PDE3A profile across patient tissues and cancer cell-line models. PDE3A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PDE3A is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, PDE3A protein abundance shows 18,840 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, COAD, and LSCC as cancer lineages where PDE3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDE3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDE3A survival associations across molecular data types. PDE3A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDE3A RNA expression–survival associations across cancer types. High PDE3A expression shows unfavorable associations in KIRP, BLCA, LUSC and ACC, but favorable associations in KIRC and UVM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PDE3A RNA expression.
This table summarizes PDE3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PDE3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDE3A shows lower tumor expression in COAD, KICH, KIRP, UCEC and BRCA and higher tumor expression in HNSC. The COAD box plot shows higher PDE3A RNA expression in normal versus tumor tissue (log2 FC = −2.471, t-test p < 0.001).
This table shows molecular features associated with PDE3A in patient tissues and cancer cell lines. In patient samples, PDE3A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PDE3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
